A humanized monovalent CD3 antibody which can activate homologous complement.
The rat monoclonal antibody (mAb) YTH12.5, specific for the CD3 antigen complex on human T cells has been modified in order to improve its efficacy in human therapy. With the aim of rendering it less immunogenic, it has been humanized using the method of framework grafting. During this process seque...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1991
|
| _version_ | 1826306397120233472 |
|---|---|
| author | Routledge, E Lloyd, I Gorman, S Clark, M Waldmann, H |
| author_facet | Routledge, E Lloyd, I Gorman, S Clark, M Waldmann, H |
| author_sort | Routledge, E |
| collection | OXFORD |
| description | The rat monoclonal antibody (mAb) YTH12.5, specific for the CD3 antigen complex on human T cells has been modified in order to improve its efficacy in human therapy. With the aim of rendering it less immunogenic, it has been humanized using the method of framework grafting. During this process sequence analysis of the YTH12.5 VL gene indicated that it was of the lambda subclass, however, it was markedly dissimilar from previously published rat and mouse V lambda gene sequences and may represent a new V lambda gene family. The humanization of this light chain represents the first successful reshaping of a lambda light chain V region. To improve the effector function of the antibody we have created a monovalent form (1 Fab, 1 Fc) using a novel method involving the introduction of an N-terminally truncated human IgG1 heavy chain gene into cells producing the humanized CD3 mAb. Comparison of the mono- and bivalent humanized mAb in a complement-mediated cell lysis assay revealed that the monovalent antibody mediated lysis of human T cell blasts whereas the bivalent form did not. The availability of a humanized, complement-fixing CD3 mAb may improve opportunities for human therapy, in the management of organ rejection, autoimmunity and the treatment of T cell lymphoma. |
| first_indexed | 2024-03-07T06:47:21Z |
| format | Journal article |
| id | oxford-uuid:fb503418-f7d7-4519-8869-8fdc9c2bb4b5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:47:21Z |
| publishDate | 1991 |
| record_format | dspace |
| spelling | oxford-uuid:fb503418-f7d7-4519-8869-8fdc9c2bb4b52022-03-27T13:12:49ZA humanized monovalent CD3 antibody which can activate homologous complement.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fb503418-f7d7-4519-8869-8fdc9c2bb4b5EnglishSymplectic Elements at Oxford1991Routledge, ELloyd, IGorman, SClark, MWaldmann, HThe rat monoclonal antibody (mAb) YTH12.5, specific for the CD3 antigen complex on human T cells has been modified in order to improve its efficacy in human therapy. With the aim of rendering it less immunogenic, it has been humanized using the method of framework grafting. During this process sequence analysis of the YTH12.5 VL gene indicated that it was of the lambda subclass, however, it was markedly dissimilar from previously published rat and mouse V lambda gene sequences and may represent a new V lambda gene family. The humanization of this light chain represents the first successful reshaping of a lambda light chain V region. To improve the effector function of the antibody we have created a monovalent form (1 Fab, 1 Fc) using a novel method involving the introduction of an N-terminally truncated human IgG1 heavy chain gene into cells producing the humanized CD3 mAb. Comparison of the mono- and bivalent humanized mAb in a complement-mediated cell lysis assay revealed that the monovalent antibody mediated lysis of human T cell blasts whereas the bivalent form did not. The availability of a humanized, complement-fixing CD3 mAb may improve opportunities for human therapy, in the management of organ rejection, autoimmunity and the treatment of T cell lymphoma. |
| spellingShingle | Routledge, E Lloyd, I Gorman, S Clark, M Waldmann, H A humanized monovalent CD3 antibody which can activate homologous complement. |
| title | A humanized monovalent CD3 antibody which can activate homologous complement. |
| title_full | A humanized monovalent CD3 antibody which can activate homologous complement. |
| title_fullStr | A humanized monovalent CD3 antibody which can activate homologous complement. |
| title_full_unstemmed | A humanized monovalent CD3 antibody which can activate homologous complement. |
| title_short | A humanized monovalent CD3 antibody which can activate homologous complement. |
| title_sort | humanized monovalent cd3 antibody which can activate homologous complement |
| work_keys_str_mv | AT routledgee ahumanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT lloydi ahumanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT gormans ahumanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT clarkm ahumanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT waldmannh ahumanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT routledgee humanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT lloydi humanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT gormans humanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT clarkm humanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement AT waldmannh humanizedmonovalentcd3antibodywhichcanactivatehomologouscomplement |